Marinus Pharmaceuticals (MRNS) Q2 2024 earnings summary

Executive summary

• ZTALMY net product revenue reached $8.0 million in Q2 2024, up 87% year-over-year, with full-year guidance reaffirmed at $33–$35 million.

• Completed enrollment in Phase 3 TrustTSC trial for tuberous sclerosis complex; topline data expected in early Q4 2024.

• ZTALMY approved in the U.S., EU, U.K., and China for CDD; commercial launches in China and Europe expected soon.

• Restructured debt agreements and initiated cost reduction plans to extend cash runway into Q2 2025.

• Net loss widened to $35.8 million for Q2 2024, reflecting higher operating expenses and restructuring costs.

Financial highlights

• Q2 2024 net product revenue was $8 million, up 87% year-over-year; H1 2024 revenue reached $15.5 million.

• Full-year 2024 ZTALMY revenue guidance maintained at $33–$35 million.

• SG&A and R&D expenses projected to decrease by 30% in H2 2024, with full-year combined expenses of $135–$140 million.

• Cash and cash equivalents at June 30, 2024: $64.7 million, expected to fund operations into Q2 2025.

• Net loss before income taxes was $35.8 million for Q2 and $74.5 million for H1 2024.

Outlook and guidance

• Top-line data from the phase III TSC trial expected in early Q4 2024; supplemental NDA submission targeted by April 2025.

• Profitability expected 12–18 months after TSC launch, with global expansion and new indications driving growth.

• Cash runway projected into Q2 2025, with additional funding required for operations beyond that.

• Anticipated commercial launches in Europe (H2 2024) and China (early 2025); potential TSC launch in H2 2025.

• Investor and analyst event scheduled for September to discuss TSC and broader oral epilepsy franchise.